Key result
Early metoprolol shows no 1-year mortality benefit over placebo in suspected acute MI.
Why the study?
The long-term prognosis after early intervention with metoprolol in suspected acute myocardial infarction was uncertain.
Does early intravenous metoprolol followed by oral treatment reduce mortality in patients with suspected acute myocardial infarction?
RCT (n=5,778)
Does early intravenous metoprolol followed by oral treatment reduce mortality in patients with suspected acute myocardial infarction?
Early intervention with metoprolol in suspected acute myocardial infarction did not improve long-term prognosis compared to placebo.
Answers are grounded in this paper and cite their sources.
No mortality benefit from early metoprolol in suspected AMI; challenges hypothesis of prognostic improvement.
A total of 5778 patients with suspected acute myocardial infarction were randomized to early intravenous metoprolol followed by oral treatment for 15 d, or to placebo. Thereafter, the two groups were treated similarly. During a 1-year follow-up period the mortality in patients who were randomized to early metoprolol was 10.6% compared to 10.7% for placebo (P greater than 0.2). Among patients with a higher risk of death, the tendency towards a reduced mortality in the metoprolol group that was observed after 15 d remained similar after 1 year. It is concluded that early intervention with metoprolol in suspected acute myocardial infarction did not improve the long-term prognosis compared to placebo treatment.
No takes yet. Share an insight, caveat, or question.
A 1991 study conducted an RCT in suspected acute myocardial infarction (n=5,778). metoprolol vs. placebo was evaluated on mortality (p=>0.2). Early intervention with metoprolol in suspected acute myocardial infarction did not improve 1-year mortality compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: